drugset / Trial / NCT02345408
Phase 1b Study of CCX872-B in Patients With Pancreatic Adenocarcinoma
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label phase 1-b study to evaluate the safety and efficacy of CCX872-B in patients with pancreatic adenocarcinoma also receiving FOLFIRINOX chemotherapy.
Timeline
- Start
- 2015-02
- Primary completion
- 2020-05-06
- Completion
- 2020-05-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CCX872-B | Small molecule | 150 mg | Oral |